Bausch Health Companies Inc. and its Salix Pharmaceuticals unit disclosed the presentation of a real-world research poster at The Liver Meeting 2026 in Denver, Colorado, on November 6, 2026, covering mortality and rehospitalization outcomes in patients hospitalized with severe alcohol-associated hepatitis.

Key Highlights

  • Study population: The research evaluated 1,630 adults in the United States hospitalized with severe alcohol-associated hepatitis.
  • 12-month survival: Estimated overall survival at 12 months was 62.0%, according to the filing.
  • Rehospitalization rate: Rehospitalization occurred in 31.4% of patients within 30 days of discharge and was estimated at 69.1% by 12 months.
  • Liver transplantation: The estimated liver transplantation rate at 12 months was 8.5%.
  • Venue: The poster (Poster 3154) was presented at The Liver Meeting 2026, November 5-9, 2026, in Denver, Colorado.
  • Listing: Bausch Health trades on NYSE:BHC and TSX: BHC.

Salix Pharmaceuticals Presents Real-World Severe AH Burden Data at AASLD 2026

Bausch Health Companies Inc. (NYSE:BHC)(TSX: BHC) and its gastroenterology business, Salix Pharmaceuticals, presented research at The Liver Meeting 2026 of the American Association for the Study of Liver Diseases, held November 5-9 in Denver, Colorado. The poster, titled "Clinical Burden and Outcomes in a Large Real-World Cohort of Patients Hospitalized with Severe Alcohol-Associated Hepatitis," was designated Poster 3154, according to the filing.

The study examined 1,630 adults in the United States who were hospitalized with severe alcohol-associated hepatitis (AH). According to the disclosure, estimated overall survival at 12 months was 62.0%. Rehospitalization occurred in 31.4% of patients within 30 days of discharge, with an estimated 12-month rehospitalization rate of 69.1%. The estimated liver transplantation rate at 12 months was 8.5%.

Jonathan Sadeh, M.D., M.Sc., Executive Vice President, Chief Medical Officer and Head of R&D at Bausch Health, was quoted in the filing as stating: "The findings of this study highlight the substantial burden of advanced liver disease and the urgent unmet need facing patients hospitalized with severe alcohol-associated hepatitis." He added that "generating real-world evidence is essential to better understanding patients' needs and informing research priorities as we work toward improving outcomes for people living with serious liver disease." The filing noted that the study "underscores the growing burden of liver disease and the need for improved management strategies and effective therapies for severe AH."

What Was Disclosed

Bausch Health and Salix Pharmaceuticals disclosed the presentation of a real-world cohort study on severe alcohol-associated hepatitis at AASLD 2026, reporting 12-month survival, rehospitalization, and liver transplantation rates drawn from 1,630 U.S. patients.